NCT05927571 - A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

Cevostamab

Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.

DRUG

Elranatamab

Elranatamab solution for injection will be administered SC as specified in each treatment arm.

DRUG

Tocilizumab

Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

Trial Locations (9)

2050

RECRUITING

Royal Prince Alfred Hospital, Camperdown

2298

RECRUITING

Calvary Mater Newcastle, Waratah

3181

RECRUITING

The Alfred Hospital, Prahan

3109600

RECRUITING

Rambam Health Care Campus, Haifa

5262000

RECRUITING

Sheba Medical Center - PPDS, Ramat Gan

6423906

RECRUITING

Tel Aviv Sourasky Medical Center PPDS, Tel Aviv

06591

RECRUITING

The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital), Seocho

03080

RECRUITING

Seoul National University Hospital, Seoul

06351

RECRUITING

Samsung Medical Center - PPDS, Seoul